ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells

International Journal of Cancer

Volumn 107, Issue 3, 2003, Pages 478-485

  Zelivianski, Stanislav ^a   Spellman, Matthew ^b   Kellerman, Mark ^b   Kakitelashvilli, Vladimir ^b   Zhou, Xia Wei ^b   Lugo, Esmeralda ^a   Lee, Ming Shyue ^a   Taylor, Rodney ^b   Davis, Thomas L ^c   Hauke, Ralph ^a   Lin, Ming Fong ^a,b,d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

^d VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

Apoptosis; Chemotherapy; ERK inhibitor; Prostate cancer

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; DOCETAXEL; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NAVELBINE; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CLINICAL PATHWAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BCL-X PROTEIN; BUTADIENES; DRUG SYNERGISM; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; PACLITAXEL; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0142059045     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11413     Document Type: Article

References (64)

1. Isaacs W, De Marzo A, Nelson WG. Focus on prostate cancer. Cancer Cell 2002;2:113-6.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001;51:15-36.
3. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993;72:3888-95.
4. Millikan RE. Chemotherapy of advanced prostatic carcinoma. Semin Oncol 1999;26:185-91.
5. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000;256:42-9.
6. Mesner PW Jr, Budihardjo II, Kaufmann SH. Chemotherapy-induced apoptosis. Adv Pharmacol 1997;41:461-99.
7. Arends MJ, Wyllie AH. Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol 1991;32:223-54.
8. Green DR. Apoptotic pathways: the roads to ruin. Cell 1998;94: 695-8.
9. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-6.
10. Farrow SN, Brown R. New members of the Bcl-2 family and their protein partners. Curr Opin Genet Dev 1996;6:45-9.
11. Cardillo M, Berchem G, Tarkington MA, Krajewski S, Krajewski M, Reed JC, Tehan T, Ortega L, Lage J, Gelmann EP. Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation. J Urol 1997;158:212-6.
12. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
13. Hamel E. Antimitotic natural products and their interactions with tubulin. Med Res Rev 1996;16:207-31.
14. Sackett DL. Vinca site agents induce structural changes in tubulin different from and antagonistic to changes induced by colchicine site agents. Biochemistry 1995;34:7010-9.
15. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998;10:123-30.
16. Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001;28:8-15.
17. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999;26:14-8.
18. Johnson SA, Harper P, Hortobagyi GN, Pouillart P. Vinorelbine: an overview. Cancer Treat Rev 1996;22:127-42.
19. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT, Goudier MJ, Chollet P, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11:1245-52.
20. Johnson SA. Vinorelbine: an update and review of activity. Clin Oncol (R Coll Radiol) 1996;8:353-7.
21. Gridelli C, Perrone F, Gallo C, De Marinis F, Ianniello G, Cigolari S, Cariello S, Di Costanzo F, D'Aprile M, Rossi A, Migliorino R, Bartolucci R, et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Eur J Cancer 1997;33:392-7.
22. Fields-Jones S, Koletsky A, Wilding G, O'Rourke M, O'Rourke T, Eckardt J, Yates B, McGuirt C, Burris HA 3rd. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial. Ann Oncol 1999;10:1307-10.
23. Culine S, Droz JP. Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress? Ann Oncol 2000; 11:1523-30.
24. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27.
25. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999; 286:1358-62.
26. Erhardt P, Schremser EJ, Cooper GM. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 1999;19:5308-15.
27. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 1997;99:1478-83.
28. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-84.
29. Price DT, Rocca GD, Guo C, Ballo MS, Schwinn DA, Luttrell LM. Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 1999;162:1537-42.
30. Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR. In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am J Pathol 1998;153:1411-23.
31. Zhang X-Q, Lee M-S, Zelivianski S, Lin MF. Characterization of a prostate-specific tyrosine phosphatase by mutagenesis and expression in human prostate cancer cells. J Biol Chem 2001;276:2544-50.
32. Zelivianski S, Verni M, Moore C, Kondrikov D, Taylor R, Lin MF. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim Biophys Acta 2001; 1539:28-43.
33. Meng TC, Lee MS, Lin MF. Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene 2000;19: 2664-77.
34. Lin MF, DaVolio J, Garcia Arenas R. Expression of human prostatic acid phosphatase activity and the growth of prostate carcinoma cells. Cancer Res 1992;52:4600-7.
35. Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH, Lin FF. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem 1998;273:5939-47.
36. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 2002;50:222-35.
37. Lin MF, Kawachi MH, Stallcup MR, Grunberg SM, Lin FF. Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. Prostate 1995;26:194-204.
38. Lin MF, Meng TC. Tyrosine phosphorylation of a 185 kDa phosphoprotein (pp185) inversely correlates with the cellular activity of human prostatic acid phosphatase. Biochem Biophys Res Commun 1996;226:206-13.
39. Meng TC, Lin MF. Tyrosine phosphorylation of c-ErbB-2 is regulated by the cellular form of prostatic acid phosphatase in human prostate cancer cells. J Biol Chem 1998;273:22096-104.
40. MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 2000;275:38953-6.
41. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22: 153-83.
42. Persons DL, Yazlovitskaya EM, Pelling JC. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 2000;275:35778-85.
43. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK-1/2 and p38 mitogen-activated protein kinase pathways. J Biol Chem 2000;275:14838-45.
44. Lieu CH, Liu CC, Yu TH, Chen KD, Chang YN, Lai YK. Role of mitogen-activated protein kinase in Taxol-induced apoptosis in human leukemic U937 cells. Cell Growth Differ 1998;9:767-76.
45. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489-94.
46. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995;92:7686-9.
47. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-45.
48. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995;92:4507-11.
49. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996;56:1253-5.
50. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148:1567-76.
51. Krajewski S, Krajewska M, Shabaik A, Wang HG, Irie S, Fong L, Reed JC. Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res 1994;54:5501-7.
52. Schmitt E, Steyaert A, Cimoli G, Bertrand R. Bax-alpha promotes apoptosis induced by cancer chemotherapy and accelerates the activation of caspase 3-like cysteine proteases in p53 double mutant B lymphoma Namalwa cells. Cell Death Differ 1998;5:506-16.
53. L. Leukemia 1999;13:1564-73.
54. L expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents. Cancer Res 2002;62: 2175-83.
55. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994;369:321-3.
56. Sato T, Hanada M, Bodrug S, Irie S, Iwama N, Boise L, Thompson C, Golemis E, Fong L, Wang H, Reed J. Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci USA 1994;91:9238-42.
57. Liu XM, Wang LG, Kreis W, Budman DR, Adams LM. Differential effect of vinorelbine versus paclitaxel on ERK-2 kinase activity during apoptosis in MCF-7 cells. Br J Cancer 2001;85:1403-11.
58. Baines P, Fisher J, Truran L, Davies E, Hallett M, Hoy T, Burnett AK. The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro. Eur J Haematol 2000;64:211-8.
59. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996;2:389-98.
60. Haldar S, Basu A, Croce CM. Bcl-2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-33.
61. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
62. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400.
63. Rothermund CA, Kondrikov D, Lin M-F, Vishwanatha JK. Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer. Prostate Cancer Prostatic Dis 2002;5:236-45.
64. Petrylak DP. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999;54:30-5.